Fibrobiologics Launches CYWC628 Drug for Clinical Trials
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 04 2026
0mins
Source: Newsfilter
Fibrobiologics Inc's stock rose by 10.34% in pre-market trading as it crossed above the 5-day SMA, reflecting positive investor sentiment.
The company has successfully released the first batch of its CYWC628 drug product for clinical trials targeting diabetic foot ulcers (DFUs), which is a significant milestone. This drug was manufactured in compliance with FDA regulations and has passed all necessary safety and quality tests, allowing the company to begin enrolling patients for its Phase 1/2 clinical trial. This trial is expected to provide critical data on the drug's safety and efficacy, further validating Fibrobiologics' fibroblast-based platform and addressing a significant market need for effective DFU treatments.
The successful launch of CYWC628 positions Fibrobiologics to capitalize on the growing demand for innovative therapies in the biotechnology sector, potentially enhancing its market presence and driving future growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FBLG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FBLG
Wall Street analysts forecast FBLG stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.930
Low
1.50
Averages
3.25
High
5.00
Current: 0.930
Low
1.50
Averages
3.25
High
5.00
About FBLG
FibroBiologics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis and certain cancers, and potential human longevity applications including thymic involution reversal. Its product candidates include CybroCell, CYMS101 and CYWC628. CybroCell is an allogeneic fibroblast cell-based therapy for degenerative disc disease. This technology is being designed as an alternative method for repairing the cartilage of the intervertebral disc (or any other articular cartilage). It is developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat multiple sclerosis (MS) and has completed the Phase I study. It is developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing. Its CYPS317 is used for the treatment of Psoriasis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FibroBiologics Unveils Preclinical Data for Psoriasis Treatment
- Preclinical Data Release: FibroBiologics presented preclinical data for its CYPS317 program at the 2026 Society for Investigative Dermatology Annual Meeting, indicating significant potential for its cell-based therapy targeting psoriasis, which may offer new treatment options for chronic disease patients.
- Efficacy and Safety: In mouse models, both HDF spheroids and single-cell HDF preparations reduced disease severity, with HDF spheroids demonstrating a more favorable systemic safety profile by avoiding immune activation associated with single-cell delivery, highlighting their importance for systemic administration.
- Immunomodulatory Effects: CYPS317 showed significant reductions in PASI scores in a chronic-relapsing psoriasis model, and histological analyses confirmed protection against epidermal thickening and immune cell infiltration, indicating its effectiveness in treatment through enhanced immune modulation.
- Strategic Implications: The Chief Scientific Officer of FibroBiologics emphasized that the fibroblast spheroid-based therapeutics have demonstrated durable immunomodulation across several chronic disease models, further solidifying CYPS317's foundation as a differentiated therapeutic approach for psoriasis patients.
See More
FibroBiologics Files New Patent for Oral Therapeutics Delivery System
- New Patent Filing: FibroBiologics has filed a new provisional patent application aimed at developing oral fibroblast and fibroblast-derived therapeutics, which could transform the treatment landscape for chronic diseases by enabling targeted delivery through the gastrointestinal tract.
- Multilayer Delivery Architecture: The patent describes a multilayer delivery platform utilizing hydrogels, nanoparticles, and pH-sensitive coatings to ensure therapeutic agents maintain viability against gastric acid and digestive enzymes, thereby enhancing therapeutic efficacy upon release in specific intestinal regions.
- Broad Indications: This platform is applicable to various chronic gastrointestinal disorders, including inflammatory bowel disease, irritable bowel syndrome, and gastrointestinal cancers, indicating its extensive potential in the treatment landscape and the possibility of significantly improving patient quality of life.
- Strategic Implications: The CEO of FibroBiologics noted that a successful oral therapeutic approach would provide a more accessible, non-invasive treatment option, potentially opening a new frontier in fibroblast-based medicine and reinforcing the company's leadership position in the biotechnology sector.
See More
FibroBiologics Expands Therapeutic Platform to Address Hantavirus
- Strategic Expansion: FibroBiologics announces the expansion of its fibroblast platform to target Hantavirus, building on preclinical work in treating acute respiratory distress syndrome (ARDS), which is expected to significantly enhance the company's competitiveness in the biotechnology sector.
- Market Demand: Hantavirus pulmonary syndrome (HPS) is a life-threatening disease with mortality rates exceeding 35-40%, and currently lacks effective antiviral therapies, indicating that FibroBiologics' therapeutic approach could fill this market gap and meet urgent patient needs for new treatments.
- Preclinical Research: Studies in ARDS models have demonstrated that fibroblasts can reduce excessive inflammatory signaling, restore endothelial barrier integrity, and promote tissue repair, mechanisms that are highly relevant to the pathophysiology of HPS, suggesting significant therapeutic potential.
- Regulatory Discussions: FibroBiologics is evaluating its fibroblast platform in Hantavirus models and plans to initiate exploratory discussions with regulatory authorities to establish a development pathway for clinical evaluation, showcasing the company's proactive approach to future market opportunities.
See More
FibroBiologics Reports Positive Results for Burn Treatment
- Preclinical Study Results: FibroBiologics' preclinical study using human dermal fibroblast spheroids for burn treatment demonstrated a significant reduction in inflammation, indicating the therapy's potential in improving burn healing.
- Gene Expression Changes: The study revealed a marked decrease in the expression of collagen synthesis-related genes (Col1a1 and Col3a1) and ECM turnover genes (Mmp1a and Mmp8) in the treatment group, suggesting the therapy may effectively inhibit excessive scarring.
- Immune Response Modulation: Post-treatment, a three-fold decrease in the pro-inflammatory marker interleukin IL-1B and a four-fold increase in the anti-inflammatory cytokine IL-10 were observed, showcasing the therapy's effectiveness in modulating immune responses.
- Market Reaction: Despite FibroBiologics' stock closing down 5.48% at $1.38 on Monday, these positive preclinical results may provide support for future market performance.
See More
FibroBiologics Releases First Batch of CYWC628 Drug for Clinical Trials
- Clinical Trial Launch: FibroBiologics has successfully released the first batch of its CYWC628 drug product, marking a significant milestone in its clinical trial for diabetic foot ulcers (DFUs), which is expected to provide new treatment options for millions of patients.
- FDA Compliance: The drug was manufactured in accordance with the U.S. FDA's current Good Manufacturing Practices (cGMP) and has passed all required safety and quality testing, ensuring its safety and efficacy for clinical use.
- R&D Platform Validation: The release of the first batch allows FibroBiologics to begin enrolling DFUs patients for its Phase 1/2 clinical trial, which will provide critical data for evaluating the safety, tolerability, and preliminary efficacy of CYWC628, further validating its fibroblast-based platform.
- Significant Market Potential: As an investigational therapy targeting DFUs, CYWC628 addresses a gap in the current market for effective long-term treatment options, which is expected to drive FibroBiologics' commercialization efforts in the biotechnology sector.
See More
FIBROBIOLOGICS UNVEILS CYWC628 DRUG FOR PHASE 1/2 CLINICAL TRIAL ON DIABETIC FOOT ULCERS
Announcement of Drug Release: FibroBiologics has announced the release of its new drug product, CYWC 628, aimed at treating Phase 1/2 diabetic foot ulcers.
Clinical Trial Focus: The drug will be utilized in clinical trials specifically designed to assess its effectiveness in managing diabetic foot ulcers.
See More
FibroBiologics Unveils Preclinical Data for Psoriasis Treatment
- Preclinical Data Release: FibroBiologics presented preclinical data for its CYPS317 program at the 2026 Society for Investigative Dermatology Annual Meeting, indicating significant potential for its cell-based therapy targeting psoriasis, which may offer new treatment options for chronic disease patients.
- Efficacy and Safety: In mouse models, both HDF spheroids and single-cell HDF preparations reduced disease severity, with HDF spheroids demonstrating a more favorable systemic safety profile by avoiding immune activation associated with single-cell delivery, highlighting their importance for systemic administration.
- Immunomodulatory Effects: CYPS317 showed significant reductions in PASI scores in a chronic-relapsing psoriasis model, and histological analyses confirmed protection against epidermal thickening and immune cell infiltration, indicating its effectiveness in treatment through enhanced immune modulation.
- Strategic Implications: The Chief Scientific Officer of FibroBiologics emphasized that the fibroblast spheroid-based therapeutics have demonstrated durable immunomodulation across several chronic disease models, further solidifying CYPS317's foundation as a differentiated therapeutic approach for psoriasis patients.
See More
FibroBiologics Files New Patent for Oral Therapeutics Delivery System
- New Patent Filing: FibroBiologics has filed a new provisional patent application aimed at developing oral fibroblast and fibroblast-derived therapeutics, which could transform the treatment landscape for chronic diseases by enabling targeted delivery through the gastrointestinal tract.
- Multilayer Delivery Architecture: The patent describes a multilayer delivery platform utilizing hydrogels, nanoparticles, and pH-sensitive coatings to ensure therapeutic agents maintain viability against gastric acid and digestive enzymes, thereby enhancing therapeutic efficacy upon release in specific intestinal regions.
- Broad Indications: This platform is applicable to various chronic gastrointestinal disorders, including inflammatory bowel disease, irritable bowel syndrome, and gastrointestinal cancers, indicating its extensive potential in the treatment landscape and the possibility of significantly improving patient quality of life.
- Strategic Implications: The CEO of FibroBiologics noted that a successful oral therapeutic approach would provide a more accessible, non-invasive treatment option, potentially opening a new frontier in fibroblast-based medicine and reinforcing the company's leadership position in the biotechnology sector.
See More
FibroBiologics Expands Therapeutic Platform to Address Hantavirus
- Strategic Expansion: FibroBiologics announces the expansion of its fibroblast platform to target Hantavirus, building on preclinical work in treating acute respiratory distress syndrome (ARDS), which is expected to significantly enhance the company's competitiveness in the biotechnology sector.
- Market Demand: Hantavirus pulmonary syndrome (HPS) is a life-threatening disease with mortality rates exceeding 35-40%, and currently lacks effective antiviral therapies, indicating that FibroBiologics' therapeutic approach could fill this market gap and meet urgent patient needs for new treatments.
- Preclinical Research: Studies in ARDS models have demonstrated that fibroblasts can reduce excessive inflammatory signaling, restore endothelial barrier integrity, and promote tissue repair, mechanisms that are highly relevant to the pathophysiology of HPS, suggesting significant therapeutic potential.
- Regulatory Discussions: FibroBiologics is evaluating its fibroblast platform in Hantavirus models and plans to initiate exploratory discussions with regulatory authorities to establish a development pathway for clinical evaluation, showcasing the company's proactive approach to future market opportunities.
See More
FibroBiologics Reports Positive Results for Burn Treatment
- Preclinical Study Results: FibroBiologics' preclinical study using human dermal fibroblast spheroids for burn treatment demonstrated a significant reduction in inflammation, indicating the therapy's potential in improving burn healing.
- Gene Expression Changes: The study revealed a marked decrease in the expression of collagen synthesis-related genes (Col1a1 and Col3a1) and ECM turnover genes (Mmp1a and Mmp8) in the treatment group, suggesting the therapy may effectively inhibit excessive scarring.
- Immune Response Modulation: Post-treatment, a three-fold decrease in the pro-inflammatory marker interleukin IL-1B and a four-fold increase in the anti-inflammatory cytokine IL-10 were observed, showcasing the therapy's effectiveness in modulating immune responses.
- Market Reaction: Despite FibroBiologics' stock closing down 5.48% at $1.38 on Monday, these positive preclinical results may provide support for future market performance.
See More
FibroBiologics Releases First Batch of CYWC628 Drug for Clinical Trials
- Clinical Trial Launch: FibroBiologics has successfully released the first batch of its CYWC628 drug product, marking a significant milestone in its clinical trial for diabetic foot ulcers (DFUs), which is expected to provide new treatment options for millions of patients.
- FDA Compliance: The drug was manufactured in accordance with the U.S. FDA's current Good Manufacturing Practices (cGMP) and has passed all required safety and quality testing, ensuring its safety and efficacy for clinical use.
- R&D Platform Validation: The release of the first batch allows FibroBiologics to begin enrolling DFUs patients for its Phase 1/2 clinical trial, which will provide critical data for evaluating the safety, tolerability, and preliminary efficacy of CYWC628, further validating its fibroblast-based platform.
- Significant Market Potential: As an investigational therapy targeting DFUs, CYWC628 addresses a gap in the current market for effective long-term treatment options, which is expected to drive FibroBiologics' commercialization efforts in the biotechnology sector.
See More
FIBROBIOLOGICS UNVEILS CYWC628 DRUG FOR PHASE 1/2 CLINICAL TRIAL ON DIABETIC FOOT ULCERS
Announcement of Drug Release: FibroBiologics has announced the release of its new drug product, CYWC 628, aimed at treating Phase 1/2 diabetic foot ulcers.
Clinical Trial Focus: The drug will be utilized in clinical trials specifically designed to assess its effectiveness in managing diabetic foot ulcers.
See More
